Tumor Antigen by Immunoassay - CA 19-9 — NCD 142 | CMS Coverage Update

TL;DR: The Centers for Medicare & Medicaid Services modified NCD 142 governing CA 19-9 tumor antigen testing, effective March 7, 2026. Here's what changes for billing teams.

CMS CA 19-9 coverage policy under NCD 142 Medicare has a narrow, specific scope — and if your team isn't billing it exactly right, you're looking at claim denial. This National Coverage Determination covers immunoassay testing of CA 19-9 serum levels as a tumor marker, but only for monitoring established diagnoses of pancreatic and biliary ductal carcinoma. The policy does not list specific CPT or HCPCS codes in the current data — but the clinical and medical necessity rules are clear, and getting them wrong is expensive.

Quick-Reference Table

CMS CA 19-9 Coverage Criteria and Medical Necessity Requirements 2026

NCD 142 is the National Coverage Determination governing Medicare coverage of CA 19-9 tumor antigen immunoassay testing. The Centers for Medicare & Medicaid Services covers this test in one specific clinical scenario: monitoring patients who already have an established diagnosis of pancreatic carcinoma or biliary ductal carcinoma.

That's the line you cannot cross. CA 19-9 testing is not covered to diagnose these cancers. It's not covered when a physician suspects malignancy but hasn't confirmed it. Medical necessity under this policy requires an existing, documented diagnosis — full stop.

The policy language is direct: "Levels are useful in following the course of patients with established diagnosis of pancreatic and biliary ductal carcinoma." Your documentation needs to reflect exactly that. The ordering physician's notes must show a confirmed diagnosis, not a rule-out or a suspicion.

On the coverage side, CMS allows the test at intervals necessary to assess two things: recurrent disease or the patient's response to treatment during subsequent treatment cycles. Neither of those is an open-ended authorization. You need documentation tying each test order to one of those two clinical purposes.

Prior authorization is not explicitly required under this national policy. But that doesn't mean your Medicare Administrative Contractor won't add requirements at the local level. Check with your MAC — some local coverage determination rules stack on top of NCD-level policy, and a local LCD could impose additional documentation or frequency limits. If you're unsure how your MAC applies this, talk to your compliance officer before the effective date of March 7, 2026.

The reimbursement risk here is straightforward. If a claim hits Medicare without documentation of an established diagnosis, it's not a gray area — it's a non-covered service under this policy. Auditors can and do pull these claims.

CMS CA 19-9 Exclusions and Non-Covered Indications

This policy has a hard exclusion, and it's the one most likely to generate a claim denial in practice.

CA 19-9 testing is explicitly not covered for "the evaluation of patients with signs or symptoms suggestive of malignancy." That phrase covers a lot of clinical ground. If a patient presents with weight loss, abdominal pain, jaundice, or elevated liver enzymes — and the physician orders CA 19-9 as part of a diagnostic workup — that test is not a covered Medicare service under NCD 142.

This is where billing teams get burned. The clinical logic feels sound. A physician is concerned about pancreatic cancer, they order a tumor marker, and the test ends up on a Medicare claim. But CMS is explicit: the policy does not cover CA 19-9 for diagnostic purposes. It covers monitoring, not diagnosis.

The real issue here is documentation at the point of order. If the physician's note says "rule out pancreatic malignancy" or "evaluate for possible biliary cancer," you have a non-covered service. The note needs to document an established diagnosis with monitoring or treatment response as the reason for testing.

This is not a new concept in oncology billing — it mirrors the logic you see in CEA and AFP tumor marker policies. CA 19-9 follows the same pattern. Monitoring = covered. Diagnosis = not covered.

Coverage Indications at a Glance

CMS CA 19-9 Billing Guidelines and Action Items 2026

The effective date is March 7, 2026. Here's what your team needs to do before then.

One more thing: don't rely solely on the ICD-10 code on the claim to establish medical necessity. The policy requires that documentation in the medical record support an established diagnosis. If your MAC audits a claim, they'll look at the chart — not just the claim form.

CPT, HCPCS, and ICD-10 Codes for CA 19-9 Tumor Antigen Testing Under NCD 142

NCD 142 as modified does not specify individual CPT, HCPCS, or ICD-10 codes in the current policy data available from CMS. This is an important gap for CA 19-9 billing teams to address directly.

What This Means for Your Billing Team

The absence of a code list in the NCD itself is not unusual — CMS sometimes publishes applicable codes through the quarterly Covered Code Lists referenced in the policy. Per the policy cross-reference, CMS directs billers to the Medicare Claims Processing Manual, Chapter 120 (Clinical Laboratory Services Based on Negotiated Rulemaking) for claims processing instructions.

Check the quarterly Covered Code Lists linked within NCD 142 on the CMS website. Those lists include the specific codes and narrative descriptions that apply to this policy. Your billing team should pull those lists and confirm you're using the correct codes for CA 19-9 immunoassay testing before March 7, 2026.

Where to Get the Code List

CMS updates the Covered Code Lists quarterly. Access them directly through the NCD 142 policy page at CMS.gov, or through the PayerPolicy source link at app.payerpolicy.org/p/cms/142-v1. Do not bill CA 19-9 claims under assumed codes — confirm against the current quarterly list.